Abstract:Metoprolol XL/amlodipine fixed-dose combination was found to be as effective and well tolerated as losartan plus amlodipine in the treatment of essential hypertension.
“…In patients who had undergone bariatric surgery, about 8% showed complete remission of diabetes while more than 90% showed a significant decrease in their insulin or OADs requirement [62]. & Laparoscopic sleeve surgery and RYBG were found to be safe and effective treatment options among obese Indian population with T2DM with significant remission rates (> 95%, p < 0.001), larger reductions in A1C, and diabetes medication usage [63][64][65]. [1,2] in consonance with ADA [3].…”
Section: Pharmacotherapy For Obese T2dmmentioning
confidence: 93%
“…& Interventions predominantly based on counselling and education are found to be effective in preventing/reducing the risk of developing diabetes and its complication and also helps in improving dietary patterns of individuals with prediabetes and diabetes [31,62]. Mobile phone messaging was found to be an inexpensive and most effective alternative way to deliver educational and motivational advice and support towards lifestyle modification in high-risk individuals [63]. & Dietary interventions such as high-carbohydrate low-fat diet [64], fiber-rich [65], and protein-rich diet [66,67]…”
Section: Evidencementioning
confidence: 99%
“…& Furthermore, some patients require a combination of two drugs in order to achieve a recommended BP target. Several Indian studies evaluated the efficacy of some FDCs, losartan 50 mg plus ramipril 2.5 mg vs each alone [62], metoprolol extended release (XL) plus amlodipine vs losartan plus amlodipine [63], and metoprolol and amlodipine [64], and reported that the FDCs were effective, safe, and well tolerated in patients with hypertension.…”
“…In patients who had undergone bariatric surgery, about 8% showed complete remission of diabetes while more than 90% showed a significant decrease in their insulin or OADs requirement [62]. & Laparoscopic sleeve surgery and RYBG were found to be safe and effective treatment options among obese Indian population with T2DM with significant remission rates (> 95%, p < 0.001), larger reductions in A1C, and diabetes medication usage [63][64][65]. [1,2] in consonance with ADA [3].…”
Section: Pharmacotherapy For Obese T2dmmentioning
confidence: 93%
“…& Interventions predominantly based on counselling and education are found to be effective in preventing/reducing the risk of developing diabetes and its complication and also helps in improving dietary patterns of individuals with prediabetes and diabetes [31,62]. Mobile phone messaging was found to be an inexpensive and most effective alternative way to deliver educational and motivational advice and support towards lifestyle modification in high-risk individuals [63]. & Dietary interventions such as high-carbohydrate low-fat diet [64], fiber-rich [65], and protein-rich diet [66,67]…”
Section: Evidencementioning
confidence: 99%
“…& Furthermore, some patients require a combination of two drugs in order to achieve a recommended BP target. Several Indian studies evaluated the efficacy of some FDCs, losartan 50 mg plus ramipril 2.5 mg vs each alone [62], metoprolol extended release (XL) plus amlodipine vs losartan plus amlodipine [63], and metoprolol and amlodipine [64], and reported that the FDCs were effective, safe, and well tolerated in patients with hypertension.…”
“…[ 285 ] Furthermore, some patients require a combination of two drugs in order to achieve a recommended BP target. Several Indian studies evaluated the efficacy of some FDCs: losartan 50 mg plus ramipril 2.5 mg vs each alone,[ 587 ] metoprolol extended release (XL) plus amlodipine vs losartan plus amlodipine,[ 588 ] metoprolol and amlodipine,[ 589 ] and reported that the FDCs were effective, safe and well-tolerated in patients with hypertension. …”
“… 91 A fixed dose combination of metoprolol extended release with amlodipine was as effective, and well tolerated as a combination of losartan and amlodipine in reducing both SBP and DBP. 92 However, combining carvedilol extended release with lisinopril was not superior to monotherapy with the either drug, except in high dose combinations, despite producing additional reduction in 24-hour mean DBP. 93 Adding nebivolol to resistant stage I-II hypertensive patients undergoing antihypertensive therapy significantly improves the response and control rate.…”
The invention of beta (β)-blockers culminated in a new era in the treatment of cardiovascular diseases (CD), and changed the course of pharmacology research for years to come. Since the introduction of propranolol into clinical practice in 1964, β-blockers enjoyed a special place in the clinicians’ armamentarium against CDs, especially for patients with ischemic heart diseases, and are still one of the most extensively used therapeutic drugs in both cardiac and non-cardiac ailments. Current uses of β-blockers in CDs include ischemic heart diseases, hypertension, cardiac arrhythmias, and heart failure. Other substantial non-cardiac uses include glaucoma, migraine, situational anxiety, benign essential tremors, and cardiac symptoms of thyrotoxicosis. This review covers some of the evolutionary changes of clinical uses of β-blockers, the rationale for their use, some recent controversies surrounding their use for treatment of hypertension, and advantages of newer additions to the group.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.